UCB BIOSCIENCES, Inc.
UCB is a global biopharmaceutical company dedicated to creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. With a history dating back to 1928, UCB focuses on innovation, sustainability, and patient support, operating in nearly 40 countries with over 9,000 employees. The company emphasizes collaboration with patients, healthcare professionals, and communities to deliver impactful medicines and solutions.
Industries
Nr. of Employees
Very Large (1000+)
UCB BIOSCIENCES, Inc.
Allée de la Recherche, 60, 1070 Brussels, Belgium
Products
Therapeutic medicines for neurology and immunology
Portfolio of prescription therapies developed for neurological and immunological disorders managed through an internal discovery-to-clinic pipeline.
Regional manufacturing and packaging capacity
Operational manufacturing and packaging sites providing oral solid-dose production and integrated biologics and small-molecule manufacturing capabilities to support product supply.
Therapeutic medicines for neurology and immunology
Portfolio of prescription therapies developed for neurological and immunological disorders managed through an internal discovery-to-clinic pipeline.
Regional manufacturing and packaging capacity
Operational manufacturing and packaging sites providing oral solid-dose production and integrated biologics and small-molecule manufacturing capabilities to support product supply.
Services
Country-specific support providing treatment information, guidance on medicine use, adverse event reporting pathways and downloadable patient materials.
Regionally available medical information teams, local safety officer contacts and pharmacovigilance reporting channels for healthcare professionals and regulatory stakeholders.
Grant funding and support mechanisms for investigator-initiated studies and external research collaborations.
Country-specific support providing treatment information, guidance on medicine use, adverse event reporting pathways and downloadable patient materials.
Regionally available medical information teams, local safety officer contacts and pharmacovigilance reporting channels for healthcare professionals and regulatory stakeholders.
Grant funding and support mechanisms for investigator-initiated studies and external research collaborations.
Expertise Areas
- Neurology therapeutic development
- Immunology therapeutic development
- Clinical trial management and clinical data interpretation
- Pharmacovigilance and regulatory safety reporting
Key Technologies
- Adeno-associated virus (AAV) vector design
- Targeted protein degradation methods
- Structural biology / X-ray crystallography
- Protein biochemistry and biophysical assays
News & Updates
An article about UCB's recent research on Thymidine Kinase deficiency and its impact on patients.
A report on the HLTH Europe 2025 event and how AI and ecosystems are transforming healthcare.
An article about UCB's initiatives in addressing myasthenia gravis.
UCB's commitment to innovation and patient impact
An overview of UCB's efforts in research, development, and patient support.
Sustainability at UCB: Building a healthier future
Details on UCB's sustainability initiatives and environmental commitments.
UCB has set and validated ambitious net-zero targets to reduce environmental impact.
An article about UCB's recent research on Thymidine Kinase deficiency and its impact on patients.
A report on the HLTH Europe 2025 event and how AI and ecosystems are transforming healthcare.
An article about UCB's initiatives in addressing myasthenia gravis.
UCB's commitment to innovation and patient impact
An overview of UCB's efforts in research, development, and patient support.
Sustainability at UCB: Building a healthier future
Details on UCB's sustainability initiatives and environmental commitments.
UCB has set and validated ambitious net-zero targets to reduce environmental impact.